Inflammatory bowel diseases (IBD) are likely driven by aberrant immune responses directed against the resident microbiota. Although IBD is commonly associated with a dysbiotic microbiota enriched in putative pathobionts, the etiological agents of IBD remain unknown.
Introduction
IBD is associated with an altered gut microbiota composition (i.e., dysbiosis) characterized by a loss of members belonging to the Firmicutes and Bacteroidetes phyla and an expansion of Proteobacteria 1 . Although cause-and-effect-relationships for disease-related dysbioses have not been established [2] [3] [4] , the microbiota associated with IBD has been hypothesized to be enriched in pathobionts-microorganisms that are thought to exert a pathological role when their relationship with the host is altered 5, 6 . Unlike frank pathogens, pathobionts presumably live symbiotic lifestyles under normal circumstances without negatively affecting host health; however, they are capable of selectively expanding during episodes of inflammation and may exacerbate the disease process 7, 8 . It is believed that pathobionts can instigate and/or perpetuate pro-inflammatory responses; however, the exact immune-microbiota interactions governing pathobiont-mediated intestinal pathology are not well understood [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Here, we explore these inter-relationships using a mouse model harboring the Altered Schaedler Flora (ASF) in which disease can be induced through the addition of the pathobiont Helicobacter bilis and a sub-pathological dose of dextran sulfate sodium (DSS) 18 . Although H. bilis and other enterohepatic Helicobacters are well-known for contributing to intestinal inflammation in immunocompromised or inflamed hosts [18] [19] [20] [21] [22] , the role of particular microbiota members in mediating pathology has not been elucidated due to the difficulty in determining specific immune-microbiome interactions in conventional animals. By using the defined ASF community in both wild-type and Rag1 -/mice, we systematically identified (i) the relative contribution of the pathobiont and the microbiota to disease severity, (ii) to what degree disease was associated with changes in the microbial community composition, (iii) the role of the adaptive immune system in disease, (iv) the specific microbes towards which immune responses were directed and (v) the contributions of immune-targeted taxa to the disease process.
Results
Pathobiont colonization can induce an equivalent degree of disease in mice with a conventional or defined microbiota. To study specific immune-microbe interactions in pathobiont-mediated colitis, we first established that a mouse model with a defined microbial community can replicate the severity of pathobiont-induced intestinal inflammation observed in the same mouse line harboring a conventional (e.g., complex and undefined) microbiota. To this end, C3H/HeN adult mice (8-10 weeks old) carrying either a conventional (Conv) microbiota or the ASF community from birth were colonized with H. bilis for three weeks prior to treatment with a sub-pathological dose of DSS (1.5%). Disease severity was not significantly different between Conv and ASF mice (Fig. 1A) , and no differences in H. bilis abundance were observed across treatments (Fig. 1B ). In addition, H. bilis-DSS-mediated inflammation did not result in major alterations to the abundances of individual bacteria or the community structure in ASF mice, except for decreased numbers of ASF 492, which was decreased in all mice treated with DSS ( Fig. 1C-D) . Homogeneity of variances analysis (Betadisper) using Bray-Curtis dissimilarity coefficients further confirmed the absence of differences in ASF community dispersion across treatments (P = 0.573) as did results from PERMANOVA (R 2 = 21.28, P = 0.003) and ANOSIM (R = 0.133) analyses, which found only minor treatment effects. Because H. bilis colonization exacerbated disease equivalently in both Conv and ASF microbiota mice following DSS treatment, this defined model now permits the study of exact immune-microbe interactions during disease.
The resident microbiota acts synergistically with the pathobiont to induce severe disease.
Having established that the pathobiont plus the ASF community are sufficient to cause disease following low-dose DSS treatment, we next determined the relative contributions of the resident microbiota and pathobiont to the pathology. Groups of adult germ-free and ASF-bearing C3H/HeN mice were colonized with or without H. bilis for three weeks and then either treated with low-dose DSS or left untreated. Histopathological evaluation of cecal tissues revealed that ASF-bearing mice colonized with H. bilis and treated with DSS developed severe intestinal lesions characterized by stromal collapse and epithelial ulceration, increased inflammatory infiltrate, submucosal edema and gland hyperplasia ( Fig. 1E and G; Fig. S1A ). In contrast, only moderate lesions were observed in mice mono-associated with H. bilis and treated with DSS. Of note, histopathological analysis demonstrated that germ-free and ASF control mice treated with 1.5% DSS developed only mild microscopic lesions, confirming that this low dose itself is subpathological ( Fig. 1E ) as previously reported 18 . Enumeration of H. bilis by qPCR revealed no significant effects of the ASF community and/or DSS treatment on pathobiont abundance ( Fig.   1F ). Thus, even though H. bilis by itself induces moderate disease following a low-dose of DSS, the presence of the ASF community is necessary for severe disease, indicating that the resident microbiota exacerbates pathobiont-mediated inflammation.
The pathobiont and resident microbiota synergistically induce a pro-inflammatory response associated with disease. Analysis of cytokine profiles from the cecal tissues of H. bilis-ASF-DSS mice showed that severe intestinal inflammation is marked by a significant increase in the production of several cytokines considered hallmarks of a Th17 response. This 6 response included elevation of TGF-ß1 and the pro-inflammatory cytokines IL-1ß, IL-17A and IL-17F ( Fig. 2A -D) as well as a corresponding decrease in production of the anti-inflammatory cytokine IL-10 ( Fig. 2E ) as compared to either H. bilis-DSS or ASF-DSS mice. IL-33 and IFN-γ production were also increased in the inflamed ceca of H. bilis-ASF-DSS mice ( Fig. S1B-C) .
Production of TNF-α and IL-22 was elevated in H. bilis-ASF versus H. bilis mono-associated mice, but DSS treatment did not further increase the secretion of either cytokine ( and P = 0.17 for WT and Rag1 -/-, respectively), ANOSIM (R statistics = 0.1331 and 0.1224 for WT and Rag1 -/-, respectively) and PERMANOVA (nearly 15% of both WT and Rag1 -/dataset variances were explained by treatments) analyses.
Pathobiont colonization triggers CD4 + Th17 cell immunoreactivity against specific
members of the resident microbiota, but not toward itself. Our finding that severe H. bilismediated disease requires a microbiota and is associated with IL-17 production led us to next determine which of the pathobiont and defined ASF bacterial community members are the actual targets of this Th17 responses. CD4 + T cells were isolated from the mesenteric lymph nodes of either germ-free or ASF-bearing C3H/HeN mice with or without H. bilis colonization for three weeks prior to low-dose DSS treatment as described in Fig. 1E . Cytokine profiles were then assessed in supernatants of these CD4 + T cells after co-culturing with mitomycin C-treated naïve splenocytes pulsed with antigens derived from either H. bilis or individual ASF members or with unpulsed splenocytes. Cytokine production was considered specific to a certain ASF member if there were significant increases over (i) unstimulated T cells isolated from the same mice, (ii) antigen-stimulated T cells harvested from equivalently-treated mice not harboring the ASF community and (iii) antigen-stimulated T cells from ASF-bearing mice treated with DSS but not colonized with H. bilis. 
Discussion
IBD is hypothesized to result from aberrant immune responses directed against gut symbionts, which can be initiated by the loss of intestinal barrier integrity [23] [24] [25] . These chronic diseases are routinely characterized by microbial dysbiosis, including overrepresentation of the phylum Proteobacteria 3,4,26-28 . Certain Proteobacteria are thought to behave as pathobionts during IBD, and much like the different virulence strategies found among frank pathogens belonging to this phylum, multiple strategies seem to have evolved in pathobionts that enable them to contribute to disease. These general strategies include altering barrier function, invading the gut epithelium, and/or stimulating local inflammatory responses, but the mechanisms through which these strategies manifest are not well known 5, 6 . To define specific mechanisms that underlie general pathobiont strategies, we focused on the pathobiont H. bilis, which is capable of triggering inflammatory disease in immunocompromised rodent models 18, [20] [21] [22] 29 . In our current model of immunosufficient, gnotobiotic mice colonized with H. bilis, a subpathological perturbation of the intestinal barrier (DSS treatment) is required for disease, but is not sufficient because severe pathology also requires a microbiota. Using a simplified microbiota (ASF), we show that H. bilis precipitates severe disease without significant increases in its own abundance and without substantial changes in gut microbial community structure. These features differentiate the pathobiont characteristics of H. bilis from other pathobionts such as the Adherent and Invasive Escherichia coli strain LF82 (AIEC LF82), which elicits chronic colitis and brings about changes in microbiota composition after disruption of innate immune signaling 11, 30 .
Perhaps the most striking characteristic of the severe intestinal inflammation observed in ASF mice colonized with H. bilis and exposed to low-dose DSS is the requirement for a microbiota. The microbiota need not be complex, as severe disease was detected in mice with a conventional community and in those harboring the simplified ASF consortium. Involvement of the microbiota in pathobiont-initiated disease has also been observed during H. hepaticus-driven colitis 32, 33 as well as during the induction of disease in immunocompromised hosts by the pathobionts P. mirabilis and K. pneumoniae 9, 10, 34 . Collectively, these studies and our own observations for H. bilis highlight the fact that multiple species of pathobiont act synergistically with resident symbionts to exacerbate pathology. It is important to note that the requirement of a microbiota for disease initiation and/or severity is not unique to pathobiont-mediated pathology.
Indeed, the magnitude of intestinal inflammation in several genetically-induced immunodeficient mouse models (IL-10 -/-, IL-2 -/-, TCR-alpha -/-) [35] [36] [37] [38] [39] also depends on one or more members of the microbiota. Thus, the microbiota can play synergistic roles in disease processes that are initiated by entirely different mechanisms (pathobiont-mediated or genetic predisposition), suggesting that its involvement may be a general feature of inflammatory intestinal diseases.
One of the most fundamental ways in which the resident microbiota can contribute to chronic intestinal inflammation is via aberrant engagement of the adaptive immune system 40 9 . We circumvented this problem by using a defined microbiota mouse model, in which H. bilis colonization and low-dose DSS treatment caused a disease phenotype indistinguishable from that of mice carrying a complex microbiota. With this reductionist approach, we were able to demonstrate that specific resident gut symbionts-primarily ASF 356 (Clostridium sp.), ASF 361 (Lactobacillus murinus) and ASF 502 (Clostridium sp.)-are the dominant targets of a Th17 response rather than the pathobiont itself. However, these Th17 targeted species are not selectively coated with IgA during disease as has been demonstrated in other models of intestinal inflammation 49 . The discordance we observed between Th17 and IgA immune reactivity may indicate that differential immune signatures could occur in IBD. Future studies will investigate how H. bilis instigates Th17 responses exclusively against the microbiota. Considering that some Helicobacter species were recently reported to precipitate antigen-specific T cell responses against themselves but not other bacterial taxa that expanded during disease, additional work to provide perspective regarding the diversity of immunological influence exerted by various Helicobacter species is warranted 55 .
The ability of H. bilis to incite CD4 + T cell responses against the microbiota, but not itself, is a novel finding that may partly explain why no single microorganism or immune response against particular microbiota members have ever been associated with inflammatory bowel diseases. Even more striking is our observation that severe pathobiont-mediated intestinal inflammation does not appear to depend on any specific member of the microbiota, as removal of the immune-dominant taxa in the ASF community altered the primary targets, but did not influence disease severity. We believe this finding is not only of mechanistic significance, but also of great importance to IBD diagnostics, because it implies that testing for changes in the development of immune responses to the gut microbiota may be of far greater diagnostic value than testing for responses to a specific pathobiont or particular member of the microbiota. To trigger disease, mice were provided with either 1.5% (for all C3H/HeN) or 2% (all C57BL/6 WT and Rag1 -/-) dextran sulfate sodium salt (DSS; MW = 36,000 -50,000, MP Biomedicals, LLC, Solon, OH) in their drinking water for 5 days, followed by a restitution period with regular water for 4 days prior to necropsy. Age-matched control animals received regular drinking water for the duration of the study. Considering previously published data 18 , each experiment measuring disease phenotype as well as immunological and bacteriological parameters consisted of at least 6-8 animals per treatment and each experiment was performed once or twice. In some experiments, sample size was adjusted to maximize statistical power as the data for most parameters measured were not normally distributed and cell samples needed to be pooled for select assays. Animals were not randomly distributed across treatments. The Institutional Animal Care and Use Committee at the University of Nebraska-Lincoln approved all procedures involving animals (Protocols 817 and 1215).
Materials and Methods

DNA isolation and quantitative real-time PCR.
DNA was isolated from feces and cecal contents as previously described using a phenol-chloroform-isoamyl alcohol and chloroformisoamyl alcohol based protocol 60 . Cecal tissue DNA was isolated using the QIAamp DNA Blood and Tissue Kit as per manufacturer instructions (QIAamp DNA Blood and Tissue Kit, Qiagen®, Germantown, MD). DNA was quantified using fluorescent molecule labeling, and all samples were diluted to a final concentration of 10 ng/µL prior to using 1 µL of the DNA template in each qPCR reaction as previously described 59 . Quantification of all ASF members in wet cecal contents and tissues was performed using previously described qPCR assays. The abundance of H. bilis was quantified using a newly designed primer set and qPCR assay 59 .
Primer sequences were Forward: 5' TGGCTTGCCAGAGCTTGA 3' and Reverse: 5' Gross and histopathological lesion scores. At necropsy, a gross cecal disease score was assigned using a previously described set of criteria 61 modified to include atrophy, emptying, enlargement of the cecal tonsil, presence of mucoid contents, and presence of intraluminal blood.
For each parameter, a score of 0 (absent) or 1 (present) was given. Final scores were additive for all parameters; the higher the final gross score, the greater the disease severity. The investigator assigning gross scores was not blinded to treatments; however, tissues from healthy control mice were always scored first to establish baseline values. To assess microscopic lesions, the apical portions of cecal tissues were collected, fixed in 10% neutral buffered formalin (Thermo Fisher Scientific Inc.) and subsequently processed, sectioned and stained with hematoxylin and eosin (H&E). Tissues were scored by a board-certified veterinary pathologist (J.M.H.) who was blinded to treatments. Cumulative histopathological scores ranged from 0-30 and were based on a 0 to 5 score for each of the following parameters adapted from a previous report 61 : gland hyperplasia, stromal collapse, edema, cellular inflammation, ulceration and mucosal height.
Higher cumulative scores represented more severe disease.
Cecal explant cultures.
Cultures of cecal fragments were prepared as previously described for colon fragments 37 . More detailed information can be found in the Supplementary Material.
CD4 + T cell stimulation. A culture system was adapted from a previously described protocol 62 as a method to provide purified CD4 + T cells with an in vitro stimulation to assess antigenspecific cytokine production in response to H. bilis or individual ASF antigens. See
Supplementary Information for more detailed information.
Cytokine quantification. Chemokine and cytokine levels (i.e., from cecal explants or CD4 + T cell supernatants) were measured using customized Mouse Cytokine/Chemokine Magnetic Bead Kits (Milliplex, Millipore, Billerica, MA) and a MAGPIX instrument (Luminex Corporation, Austin, TX), except for TGF-ß1, which was measured using a Mouse TGF-ß1 ELISA Ready-SET-Go (eBioscience Inc.) as per manufacturer instructions.
Flow cytometry. Immune cell phenotypes were assessed as previously described 63, 64 . See
Supplementary Information for more detailed information and schematics of gating strategies ( Fig. S11A -E and S12A-F).
Immunoglobulin A (IgA)-based bacterial cell sorting and quantification. This method was adapted from a previously published work 49 . A detailed description of the protocol used for bacterial cell sorting and quantification can be found in the Supplementary Material. Data availability. R scripts and raw data for the ecological analysis (i.e., ASF community structure and correlation analysis) are accessible at https://github.com/jcgneto/HbilisASFmodel.
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